Financial Results for Full Year 2007: NicOx Significantly Advances Clinica... (pment of its NLA program which includes ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

Date:3/3/2008

pment of its NLA program, which includes candidates other than

NicOx' NCX 1510. A potential partnership and further development of the

NLA program may include NCX 1510 or could exclude NCX 1510 and instead

focus on other formulations of Orexo's NLA technology

-- In October 2007, NicOx and Ferrer Grupo International jointly presented

clinical and preclinical results from their collaboration at the 21st

World Congress of Dermatology

-- In July 2007, NicOx appointed Pascal Pfister MD as Chief Scientific

Officer (CSO). Dr. Pfister reports to Michele Garufi, Chairman and CEO,

and has overall responsibility for NicOx' Research and Development

(R&D) activities. Dr. Pfister brings extensive experience and

leadership to NicOx from his 19 year career at Novartis and Sandoz

-- In October 2007, NicOx opened its U.S. headquarters in Warren, New

Jersey, where the Company has based its newly established Commercial

Affairs and North American Clinical Operations departments. This

followed the appointment of Sanjiv Sharma as Vice President of

Commercial Affairs in April 2007, who is also head of the U.S. Office.

Sanjiv brings extensive marketing and sales management experience to

NicOx, from his previous positions at Biovail Pharmaceutical Inc. and

Sanofi-Aventis and its predecessor companies

Review of the financial results on December 31, 2007 and 2006:

Revenues

In 2007, NicOx' revenues increased by euro 11.0 million to reach euro 20.6 million, compared to euro 9.6 million in 2006. This significant increase results from the following payments that were entirely recognized as revenues in 2007:

-- Euro 5.0 million received from Merck in January 2007, following the

initiation of toxicology studies on the first development candidate

which had been recently selected, in the
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results

Post Your Comments:

Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2 Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 1 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 2 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 3 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 4 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 5 Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns 54934 6 President Obama Misleads on Abortion Funding in Health Care Reform 54931 1 President Obama Misleads on Abortion Funding in Health Care Reform 54931 2 Kaiser Workers Launch Statewide Pickets 54929 1

[0] Hill-Rom Announces Appointment of James R. Giertz to Board of Directors [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks Savient Provides Update on Pegloticase BLA

Breaking Medicine News(10 mins):Health News:Pitt study suggests craving hinders comprehension without your realizing it 2 Health News:Lilly Announces the First 300-unit Vial of Insulin 2 Health News:Lilly Announces the First 300-unit Vial of Insulin 3 Health News:Lilly Announces the First 300-unit Vial of Insulin 4 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4 Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5 Health News:Pitt study suggests craving hinders comprehension without you realizing it 2 Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2 Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3

[0] Pitt study suggests craving hinders comprehension without your realizing it [0] Lilly Announces the First 300-unit Vial of Insulin [0] Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management [0] Pitt study suggests craving hinders comprehension without you realizing it [1] Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange

Julie L. Novak Named Executive Director of Michigan State Medical Society Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 National Health Care Coalition Commends New Congress' Focus on Fighting Chronic Disease in House Stimulus Package Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009 Optelec and ShopLowVision.com Bring Life Back Into Focus at ATIA 2009 Orlando Patients' Bath Basins Increase Risk for Hospital-Acquired Infections

Medicine Products:

Nucleus Chopper - P. Koch Magstim 200 Disposable Laser Fiber (For 12 Watt Laser)Single Use, 20 Gauge Illumination Probe

Financial Results for Full Year 2007: NicOx Significantly Advances Clinica...(pment of its NLA program which includes ...),Health